7/1/2013

GlaxoSmithKline's drisapersen received breakthrough therapy designation from the FDA as a potential treatment for Duchenne muscular dystrophy. The drug, licensed from Dutch firm Prosensa, is being evaluated in ambulant and nonambulant boys with dystrophin gene mutations.

Full Story:
PharmaTimes (U.K.)

Related Summaries